S93 Autoimmune Hemolytic Anemia Occurring After Laparoscopic Total Colectomy With Ileorectal Anastomosis in a Patient With Ulcerative Colitis: A Case report
{"title":"S93 Autoimmune Hemolytic Anemia Occurring After Laparoscopic Total Colectomy With Ileorectal Anastomosis in a Patient With Ulcerative Colitis: A Case report","authors":"Taehyung Kim, Soo Jeong Kim","doi":"10.14309/01.ajg.0000996116.52805.3b","DOIUrl":null,"url":null,"abstract":".Thiscaseseriespresented4patientswithCDwhoreceivedsirolimustherapyforaprimaryindicationofrefractoryCD.Allpatientshadfailedtreatmentwithatleast6otherIBD-therapies. Our results reveal 1 of 4 patients reporting symptomatic improvement and whilst treatment escalation was not required, imaging measures of in fl ammation remained equivocal. Furthermore, all 4 patients required sirolimus discontinuation due to adverse e ff ects. With minimal data currently available for use of sirolimus therapy in adults with refractory IBD, our fi ndings suggest that its role may be limited by treatment-derived adverse e ff ects. Further large-scale studies are needed to investigate the e ffi ciency of sirolimus therapy in refractory IBD, with particular attention to treatment-limiting adverse e ff ects.","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"137 ","pages":"S25 - S26"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000996116.52805.3b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
.Thiscaseseriespresented4patientswithCDwhoreceivedsirolimustherapyforaprimaryindicationofrefractoryCD.Allpatientshadfailedtreatmentwithatleast6otherIBD-therapies. Our results reveal 1 of 4 patients reporting symptomatic improvement and whilst treatment escalation was not required, imaging measures of in fl ammation remained equivocal. Furthermore, all 4 patients required sirolimus discontinuation due to adverse e ff ects. With minimal data currently available for use of sirolimus therapy in adults with refractory IBD, our fi ndings suggest that its role may be limited by treatment-derived adverse e ff ects. Further large-scale studies are needed to investigate the e ffi ciency of sirolimus therapy in refractory IBD, with particular attention to treatment-limiting adverse e ff ects.